Deciphera Pharmaceuticals (NASDAQ:DCPH) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.
Profitability
This table compares Deciphera Pharmaceuticals and VBI Vaccines' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Deciphera Pharmaceuticals | N/A | -45.02% | -40.12% |
| VBI Vaccines | -2,837.73% | -36.69% | -28.29% |
Risk and Volatility
Deciphera Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.
Valuation & Earnings
This table compares Deciphera Pharmaceuticals and VBI Vaccines' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Deciphera Pharmaceuticals | $25 million | 101.54 | $-192,260,000.00 | ($4.48) | -9.83 |
| VBI Vaccines | $2.22 million | 313.50 | $-54,810,000.00 | ($0.46) | -5.96 |
VBI Vaccines has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of VBI Vaccines shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Deciphera Pharmaceuticals and VBI Vaccines, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Deciphera Pharmaceuticals | 0 | 3 | 7 | 0 | 2.70 |
| VBI Vaccines | 0 | 0 | 3 | 1 | 3.25 |
Deciphera Pharmaceuticals currently has a consensus target price of $70.30, indicating a potential upside of 59.59%. VBI Vaccines has a consensus target price of $7.00, indicating a potential upside of 155.47%. Given VBI Vaccines' stronger consensus rating and higher probable upside, analysts plainly believe VBI Vaccines is more favorable than Deciphera Pharmaceuticals.
Summary
VBI Vaccines beats Deciphera Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
